Results 81 to 90 of about 6,967 (165)

Renoprotective effects of combination therapy with tolvaptan and dapagliflozin in autosomal dominant polycystic kidney disease: a four-case series. [PDF]

CEN Case Rep
Nishida J, Yamakawa M, Miura S, Yasutomi M.   +3 more
europepmc   +1 more source

Potential amelioration of liver function by low-dose tolvaptan in heart failure patients. [PDF]

Toxicol Rep
Mino Y, Hoshikawa K, Naito T, Akutsu S, Imoto Y, Nakatsugawa E, Saotome M, Maekawa Y, Kawakami J.   +8 more
europepmc   +1 more source

No relationship between total kindey volume class or genotype and 24h blood pressure control in adult ADPKD patients [PDF]

, 2018
Allamani, Mandelina, Devos, Hannes, Schots, Lisa, Tonnelier, Annelies, Van der Niepen, Patricia   +4 more
core   +2 more sources

Autosomal Dominant Polycystic Kidney Disease-Related Multifocal Renal Cell Carcinoma: A Narrative Iconographic Review. [PDF]

Int J Mol Sci
Sergi CM, Guerra L, Hager J.
europepmc   +1 more source

Effectiveness of Tolvaptan for Autosomal Dominant Polycystic Kidney Disease in US Clinical Practice With Comparison to Historical Control Data. [PDF]

Kidney Med
Perrone RD, Garbinsky D, Nunna S, Gandhi HK, Fernandes AW, Burgos G, Olopoenia A, DeCongelio M, Maculaitis MC, Zhou X.   +9 more
europepmc   +1 more source

Immunotherapy for Unresectable Stage III Non-Small-Cell Lung Cancer. [PDF]

, 2017
Peters, S., Rizvi, N.A.
core   +1 more source

The management of polycystic liver disease by tolvaptan

Clinical and Molecular Hepatology, 2020
Masaki Kitajima, Soichiro Miura, Tsuneo Takenaka   +2 more
openaire   +3 more sources

Five years of post-marketing liver safety data from the tolvaptan Risk Evaluation and Mitigation Strategy. [PDF]

Clin Kidney J
Lohrmann E, Jaeger T, Enekebe K, Zhang Z, Wilt T, Riggen M, Stemhagen A, Nair I, Nunna S, Fernandes AW, Gandhi H, Sergeyeva O, George V.   +12 more
europepmc   +1 more source

The Role of Baseline Total Kidney Volume Growth Rate in Predicting Tolvaptan Efficacy for ADPKD Patients: A Feasibility Study. [PDF]

J Clin Med
Dev H, Hu Z, Blumenfeld JD, Sharbatdaran A, Kim Y, Zhu C, Shimonov D, Chevalier JM, Donahue S, Wu A, RoyChoudhury A, He X, Prince MR.   +12 more
europepmc   +1 more source

Commentary: Tolvaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) - an update. [PDF]

BMC Nephrol
Gittus M, Haley H, Harris T, Borrows S, Padmanabhan N, Gale D, Simms R, Williams T, Acquaye A, Wong A, Chan M, Lee E, Ong AC.   +12 more
europepmc   +1 more source